Principles for evidence-based drug formulary policy (Q34724227)

4 August 2017

Principles for evidence-based drug formulary policy (English)

1 reference

4 August 2017

2

Bruce M Psaty

1 reference

4 August 2017

Gregory E Simon

1

1 reference

4 August 2017

Jennifer Berg Hrachovec

series ordinal

3

1 reference

4 August 2017

Marc Mora

series ordinal

4

1 reference

4 August 2017

1 October 2005

1 reference

Journal of General Internal Medicine

4 August 2017

1 reference

4 August 2017

20

1 reference

4 August 2017

10

1 reference

4 August 2017

964-968

1 reference

https://scigraph.springernature.com/pub.10.1111/j.1525-1497.2005.0232.x

4 August 2017

0 references

cites work

Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Pharmacy benefits and the use of drugs by the chronically ill.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Evidence-based and value-based formulary guidelines

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

The effect of incentive-based formularies on prescription-drug utilization and spending

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Should evidence-based proof of drug efficacy be extrapolated to a "class of agents"?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Pharmacogenetics of antidepressant medication intolerance

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Comorbid mood disorders and medical illness: a Food and Drug Administration perspective

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Evidence b(i)ased medicine--selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

America's other drug problem: how the drug industry distorts medicine and politics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Promotion of prescription drugs to consumers.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Evidence-based coverage policy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Economic evaluation of rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs for the treatment of osteoarthritis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland

7 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

7 July 2018

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

A systematic review of newer pharmacotherapies for depression in adults: evidence report summary

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Impact of therapeutic interchange from pravastatin to lovastatin in a Veterans Affairs Medical Center

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Surrogate end points in clinical trials: are we being misled?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Does intolerance or lack of response with fluoxetine predict the same will happen with sertraline?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Health spending rebound continues in 2002.

7 July 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

The impact of a national prescription drug formulary on prices, market share, and spending: lessons for Medicare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

An ethical template for pharmacy benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

The ethics of Pharmaceutical benefit management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

The Academy of Managed Care Pharmacy Format for Formulary Submissions: an evolving standard--a Foundation for Managed Care Pharmacy Task Force report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Reporting of 6-month vs 12-month data in a clinical trial of celecoxib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Choosing a first-line antidepressant: equal on average does not mean equal for everyone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Under-reporting of clinical trials is unethical.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Using pharmacogenetics to improve drug safety and efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1525-1497.2005.0232.X

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1490223

A 3-stage model for assessing the probable economic effects of direct-to-consumer advertising of pharmaceuticals

26 October 2018

1 reference

12 December 2020

Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans

1 reference

12 December 2020

Looking inside the nation's medicine cabinet: trends in outpatient drug spending by Medicare beneficiaries, 1997 and 2001

1 reference

12 December 2020

Therapeutic interchange of conjugated and esterified estrogens in a managed care organization

1 reference

12 December 2020

Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease

1 reference

12 December 2020

Effect of prescription benefit changes on medical care utilization in a Medicare HMO population

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

10.1111/J.1525-1497.2005.0232.X

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference

4 August 2017

1 reference